Cargando…

CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease

Metabolic dysfunction-associated fatty liver disease (MAFLD), previously called metabolic nonalcoholic fatty liver disease, is the most prevalent chronic liver disease worldwide. The multi-factorial nature of MAFLD severity is delineated through an intricate composite analysis of the grade of activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Na, Yan, Gang, Tang, Maowen, Wu, Yuhui, Song, Fasong, Xia, Xing, Chan, Lawrence Wing-Chi, Lei, Pinggui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661153/
https://www.ncbi.nlm.nih.gov/pubmed/37985560
http://dx.doi.org/10.1186/s41747-023-00387-0
_version_ 1785148456462974976
author Hu, Na
Yan, Gang
Tang, Maowen
Wu, Yuhui
Song, Fasong
Xia, Xing
Chan, Lawrence Wing-Chi
Lei, Pinggui
author_facet Hu, Na
Yan, Gang
Tang, Maowen
Wu, Yuhui
Song, Fasong
Xia, Xing
Chan, Lawrence Wing-Chi
Lei, Pinggui
author_sort Hu, Na
collection PubMed
description Metabolic dysfunction-associated fatty liver disease (MAFLD), previously called metabolic nonalcoholic fatty liver disease, is the most prevalent chronic liver disease worldwide. The multi-factorial nature of MAFLD severity is delineated through an intricate composite analysis of the grade of activity in concert with the stage of fibrosis. Despite the preeminence of liver biopsy as the diagnostic and staging reference standard, its invasive nature, pronounced interobserver variability, and potential for deleterious effects (encompassing pain, infection, and even fatality) underscore the need for viable alternatives. We reviewed computed tomography (CT)-based methods for hepatic steatosis quantification (liver-to-spleen ratio; single-energy “quantitative” CT; dual-energy CT; deep learning-based methods; photon-counting CT) and hepatic fibrosis staging (morphology-based CT methods; contrast-enhanced CT biomarkers; dedicated postprocessing methods including liver surface nodularity, liver segmental volume ratio, texture analysis, deep learning methods, and radiomics). For dual-energy and photon-counting CT, the role of virtual non-contrast images and material decomposition is illustrated. For contrast-enhanced CT, normalized iodine concentration and extracellular volume fraction are explained. The applicability and salience of these approaches for clinical diagnosis and quantification of MAFLD are discussed. Relevance statement CT offers a variety of methods for the assessment of metabolic dysfunction-associated fatty liver disease by quantifying steatosis and staging fibrosis. Key points • MAFLD is the most prevalent chronic liver disease worldwide and is rapidly increasing. • Both hardware and software CT advances with high potential for MAFLD assessment have been observed in the last two decades. • Effective estimate of liver steatosis and staging of liver fibrosis can be possible through CT. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10661153
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-106611532023-11-21 CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease Hu, Na Yan, Gang Tang, Maowen Wu, Yuhui Song, Fasong Xia, Xing Chan, Lawrence Wing-Chi Lei, Pinggui Eur Radiol Exp Narrative Review Metabolic dysfunction-associated fatty liver disease (MAFLD), previously called metabolic nonalcoholic fatty liver disease, is the most prevalent chronic liver disease worldwide. The multi-factorial nature of MAFLD severity is delineated through an intricate composite analysis of the grade of activity in concert with the stage of fibrosis. Despite the preeminence of liver biopsy as the diagnostic and staging reference standard, its invasive nature, pronounced interobserver variability, and potential for deleterious effects (encompassing pain, infection, and even fatality) underscore the need for viable alternatives. We reviewed computed tomography (CT)-based methods for hepatic steatosis quantification (liver-to-spleen ratio; single-energy “quantitative” CT; dual-energy CT; deep learning-based methods; photon-counting CT) and hepatic fibrosis staging (morphology-based CT methods; contrast-enhanced CT biomarkers; dedicated postprocessing methods including liver surface nodularity, liver segmental volume ratio, texture analysis, deep learning methods, and radiomics). For dual-energy and photon-counting CT, the role of virtual non-contrast images and material decomposition is illustrated. For contrast-enhanced CT, normalized iodine concentration and extracellular volume fraction are explained. The applicability and salience of these approaches for clinical diagnosis and quantification of MAFLD are discussed. Relevance statement CT offers a variety of methods for the assessment of metabolic dysfunction-associated fatty liver disease by quantifying steatosis and staging fibrosis. Key points • MAFLD is the most prevalent chronic liver disease worldwide and is rapidly increasing. • Both hardware and software CT advances with high potential for MAFLD assessment have been observed in the last two decades. • Effective estimate of liver steatosis and staging of liver fibrosis can be possible through CT. GRAPHICAL ABSTRACT: [Image: see text] Springer Vienna 2023-11-21 /pmc/articles/PMC10661153/ /pubmed/37985560 http://dx.doi.org/10.1186/s41747-023-00387-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Narrative Review
Hu, Na
Yan, Gang
Tang, Maowen
Wu, Yuhui
Song, Fasong
Xia, Xing
Chan, Lawrence Wing-Chi
Lei, Pinggui
CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease
title CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease
title_full CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease
title_fullStr CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease
title_full_unstemmed CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease
title_short CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease
title_sort ct-based methods for assessment of metabolic dysfunction associated with fatty liver disease
topic Narrative Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661153/
https://www.ncbi.nlm.nih.gov/pubmed/37985560
http://dx.doi.org/10.1186/s41747-023-00387-0
work_keys_str_mv AT huna ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease
AT yangang ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease
AT tangmaowen ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease
AT wuyuhui ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease
AT songfasong ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease
AT xiaxing ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease
AT chanlawrencewingchi ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease
AT leipinggui ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease